In total, 47 specimens of human LSCC tissues and adjacent tissues were obtained from the Tianjin Union Medicine Centre (Tianjin, China). Samples were allocated into two groups: an experimental group (tumor tissues) and a control group (adjacent tissues). The study was performed according to the institutional ethical guidelines. The ethics committee of Tianjin Union Medicine Centre approved a written informed consent form which was signed by every patient, and all the consents were saved by the ethics committee. The conduct of the study was in accordance with the principles expressed in the Declaration of Helsinki. All samples were snap-frozen in liquid nitrogen, then stored at –80°C for further use.
Normal esophageal cell Het-1A and laryngeal squamous carcinoma cells TU686 and TU177 came from BeNa Culture Collection (Beijing, China). Cells were cultivated in Roswell Park Memorial Institute (RPMI) 1640 culture medium supplemented with 10% fetal bovine serum (FBS, TBD, Tianjin, China), 100 units/ml penicillin G and 100 µg/ml streptomycin and incubated in a 5% CO2 humidified atmosphere at 37°C. Cisplatin (DDP)-resistance (R) laryngeal squamous carcinoma cells (TU686-DDP-R, TU177-DDP-R) came from TU686 and TU177 cells with continuous cisplatin treatment.
Normal esophageal cell Het-1A and laryngeal squamous carcinoma cells TU686 and TU177 came from BeNa Culture Collection (Beijing, China). Cells were cultivated in Roswell Park Memorial Institute (RPMI) 1640 culture medium supplemented with 10% fetal bovine serum (FBS, TBD, Tianjin, China), 100 units/ml penicillin G and 100 µg/ml streptomycin and incubated in a 5% CO2 humidified atmosphere at 37°C. Cisplatin (DDP)-resistance (R) laryngeal squamous carcinoma cells (TU686-DDP-R, TU177-DDP-R) came from TU686 and TU177 cells with continuous cisplatin treatment.